Guillaume M.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
- Phase II Randomized Trial of Ibrutinib, Venetoclax, and CD20 Antibody Therapy in Untreated Mantle Cell Lymphoma Patients
- Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
Data & Insights
Has run more than one trial at 18 of 102 partner sites.
Specializations
Lymphoma Research
This investigator specializes in the treatment of classical Hodgkin Lymphoma, with particular emphasis on developing innovative therapeutic approaches for both newly diagnosed and treatment-resistant cases.
- Newly Diagnosed cHL Treatment
- Refractory Disease Management
- Combined Therapy Approaches
The investigator's work encompasses evaluation of response rates in novel treatment combinations and assessment of disease progression using specialized criteria.
Immunotherapy Focus
The researcher demonstrates particular interest in immunotherapeutic interventions, including studies with pembrolizumab and exploration of alternative treatment pathways for patients who have not responded to conventional therapies.
- PD-(L)1 Therapy Research
- Immunotherapy Combinations
- Treatment Resistance Patterns
Their work includes investigation of therapeutic options for patients with relapsed disease and evaluation of novel drug combinations.
Treatment Assessment
The investigator utilizes Lugano response criteria for comprehensive evaluation of treatment effectiveness, focusing on both immediate and long-term patient outcomes in lymphoma care.
- Response Rate Assessment
- Progression-Free Survival Studies
- Independent Review Protocols
Their research incorporates central review methodologies to ensure objective assessment of treatment responses.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.